We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molgen Presents Diagnostics Chemistry, Flows and Systems at MEDICA 2021

By LabMedica International staff writers
Posted on 15 Nov 2021
Print article
Image: PUREPREP 96 (Photo courtesy of MolGen B.V.)
Image: PUREPREP 96 (Photo courtesy of MolGen B.V.)

MolGen B.V. (Veenendaal, Netherlands) presented its diagnostics chemistry, flows and systems at MEDICA 2021, the largest medical trade fair in the world that has been taking place for more than four decades. Over the years, the event has attracted several thousand exhibitors from more than 50 countries. Leading individuals from the fields of business, research, and politics attended MEDICA 2021, alongside tens of thousands of national and international experts and decision-makers from the sector. MolGen took advantage of the opportunity to connect with the global leaders in clinical chemistry, molecular diagnostics, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

At MEDICA 2021, MolGen showcased and demonstrated its latest products and services, including technology, systems, reagents and consumables for human diagnostics and pharmaceutical sciences. MolGen demonstrated its PurePrep 96 automated DNA and RNA purification system which is suitable for high throughput workflows with up to 96 samples per run and process samples up to 1ml. The device uses magnetic separation technology for different matrices like blood, cultured cells, bacteria, tissues, cell-free body fluids, and plant samples. The small-footprint system enables high-speed, high-quality processing with magnetic rods used to transfer magnetic beads through the various purification phases of mixing, binding, washing and elution resulting in purified DNA and RNA.

MolGen also showcased its PurePrep TTR high throughput automated liquid handling device that transfers liquid fast, accurately, and consistently from tubes to Deep Well microtiter plates. Both the tubes and plates are equipped with barcodes read by scanners to track and trace samples throughout the complete workflow. This system is developed to decrease the hands-on time, increase the lab’s accuracy, reduce contamination risks by decapping and capping tubes, and transfer samples from the tubes to plates. It is optimized for processing PurePrep TL+ samples.

Additionally, MolGen highlighted its PurePrep FR automated liquid handler for filling plates with high precision and decreasing hands-on time. It is ideal for downstream processing setups, like the PCR and LAMP setup. This system is easy to adjust to different procedures and provides insight into the results. Also on display was the MolGen Sealer, a semi-automatic thermal sealer which is ideal for low to medium throughput laboratories that requires uniform and consistent sealing of micro-plates. Unlike manual plate sealing, the MolGen Sealer produces consistent plate seals. With flexible temperature, time and pressure settings, the sealing conditions are easily optimized to guarantee consistent results, produce 100% tight seals, and eliminate sample loss or evaporation. Offering complete versatility, the MolGen Sealer is compatible with a full range of plates for PCR, assay or storage applications, and can be used with plates ranging from standard height to deep well.

Related Links:
MolGen B.V.

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.